Billionaire investor Carl Icahn said on Tuesday he had acquired a “large position” in Botox-maker Allergan and that he was very supportive of CEO Brent Saunders.

Shares of Allergan rose 2.6 percent to $242 in early trading.

Icahn, who did not disclose details of the stake, said he was confident in Saunders’ ability to enhance value for all Allergan shareholders.

Icahn, who launched a $150 million political action committee advocating tax reform to eliminate inversions, was firmly against the now-terminated Pfizer-Allergan deal, saying it would result in the loss of the country’s 10th-largest company to Ireland.